Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 436 results for cardiovascular disease

  1. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  2. What is the effectivness of statin treatment in older people?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  3. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  4. Automated blood pressure monitoring in people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial fibrillation?

    monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  5. Blood pressure targets for people with aortic aneurysm: What are the optimal blood pressure targets in adults with hypertension and aortic aneurysm, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  6. Blood pressure targets for people with prior ischaemic or haemorrhagic stroke: What are the optimal blood pressure targets in adults with prior ischaemic or haemorrhagic stroke, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  7. Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    4 January 2023
    View recommendations

    Sections for TA856

  8. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    . Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  9. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...

    Research recommendation
    Published
    9 June 2015

  10. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

    Technology appraisal guidance
    Published
    30 September 2022
    View recommendations

    Sections for TA829

  11. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA561

  12. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015

  13. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    adults unless contraindicated (adults over 65 or with a history of cardiovascular disease). Although evidence about dosing was very...

    Research recommendation
    Published
    10 February 2020

  14. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

    HealthTech guidance
    Published
    26 August 2020
    View recommendations

    Sections for HTG552

  15. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

    Clinical guideline
    Published
    13 November 2013